Study of RXDX-105, Potent RET Inhibitor in Patients With Advanced Lung Cancer and Other Solid Tumors
Completed · Phase 1
Conditions studied: Solid Tumors
In brief
This is a first-in-human, multicenter, open-label study consisting of 2 phases. Phase 1 is a dose escalation study of RXDX-105 (formerly known as CEP-32496) in patients with advanced solid tumors aimed at defining the recommended Phase 2 dose (RP2D) and schedule for administration. Phase 1b is a dose expansion in approximately 90 patients with advanced solid tumors with specific histologies and/or molecular alterations of interest. Patients in Phase 1b will be treated at the RP2D determined in Phase 1.
Key facts
- Study ID
- NCT01877811
- Run by
- Hoffmann-La Roche
- People needed
- 143
- Starts
- 2013-06-01
- Expected to finish
- 2019-02-01
- Last updated by the study team
- 2019-04-25
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- City of Hope — Duarte, California, United States
- University of California Irvine College of Medicine — Irvine, California, United States
- University of California San Diego Moores Cancer Center — San Diego, California, United States
- Lombardi Comprehensive Cancer Center, Georgetown — Washington D.C., District of Columbia, United States
- Florida Cancer Center — Sarasota, Florida, United States
- University Cancer & Blood Center, LLC — Athens, Georgia, United States
- Massachusetts General Hospital/Beth Israel Deaconess Med. Ctr./Dana Farber Cancer Institute — Boston, Massachusetts, United States
- Henry Ford Health System — Detroit, Michigan, United States
- Karmanos Cancer Center — Detroit, Michigan, United States
- Washington University — St Louis, Missouri, United States
- Memorial Sloan Kettering Cancer Center — New York, New York, United States
- Fox Chase Cancer Center — Philadelphia, Pennsylvania, United States
- University of Texas MD Anderson Cancer Center — Houston, Texas, United States
- University of Washington, Seattle Cancer Care Alliance — Seattle, Washington, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.